Insider Selling: Orthofix International N.V. (OFIX) CEO Sells 5,000 Shares of Stock
Orthofix International N.V. (NASDAQ:OFIX) CEO Brad Mason sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, November 28th. The shares were sold at an average price of $53.48, for a total value of $267,400.00. Following the transaction, the chief executive officer now directly owns 183,053 shares in the company, valued at $9,789,674.44. The sale was disclosed in a document filed with the SEC, which is available at this link.
Shares of Orthofix International N.V. (NASDAQ OFIX) traded up $0.07 during midday trading on Thursday, hitting $54.22. The company had a trading volume of 99,525 shares, compared to its average volume of 149,435. The stock has a market cap of $981.01, a PE ratio of 35.17, a price-to-earnings-growth ratio of 2.67 and a beta of 0.15. Orthofix International N.V. has a 52 week low of $32.51 and a 52 week high of $54.73.
Orthofix International (NASDAQ:OFIX) last announced its quarterly earnings data on Monday, October 30th. The medical device company reported $0.42 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.41 by $0.01. Orthofix International had a return on equity of 10.26% and a net margin of 0.33%. The company had revenue of $105.30 million for the quarter, compared to analysts’ expectations of $100.67 million. During the same period last year, the firm posted $0.36 EPS. Orthofix International’s revenue for the quarter was up 6.9% compared to the same quarter last year. equities analysts forecast that Orthofix International N.V. will post 1.61 EPS for the current year.
A number of equities analysts recently weighed in on OFIX shares. TheStreet raised Orthofix International from a “c+” rating to a “b-” rating in a report on Tuesday, August 8th. BidaskClub raised Orthofix International from a “hold” rating to a “buy” rating in a report on Thursday, August 17th. Jefferies Group reissued a “buy” rating and set a $55.00 price objective (up from $50.00) on shares of Orthofix International in a report on Thursday, August 10th. Zacks Investment Research raised Orthofix International from a “hold” rating to a “buy” rating and set a $54.00 price objective on the stock in a report on Thursday, August 10th. Finally, BTIG Research set a $56.00 price objective on Orthofix International and gave the company a “buy” rating in a report on Monday, October 30th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Orthofix International has an average rating of “Buy” and a consensus price target of $54.42.
About Orthofix International
Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.
Receive News & Ratings for Orthofix International N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International N.V. and related companies with MarketBeat.com's FREE daily email newsletter.